Flossbach Von Storch AG Has $3.13 Million Stock Holdings in Amgen, Inc. (NASDAQ:AMGN)
Flossbach Von Storch AG grew its holdings in Amgen, Inc. (NASDAQ:AMGN) by 243.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,440 shares of the medical research company’s stock after purchasing an additional 10,950 shares during the quarter. Flossbach Von Storch AG’s holdings in Amgen were worth $3,130,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors have also made changes to their positions in AMGN. Savior LLC acquired a new position in shares of Amgen in the 4th quarter valued at about $34,000. Harel Insurance Investments & Financial Services Ltd. raised its stake in Amgen by 830.4% during the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,042 shares of the medical research company’s stock worth $251,000 after buying an additional 930 shares during the period. Davis R M Inc. raised its stake in Amgen by 5.6% during the 4th quarter. Davis R M Inc. now owns 7,322 shares of the medical research company’s stock worth $1,765,000 after buying an additional 386 shares during the period. Global Retirement Partners LLC raised its stake in Amgen by 4.6% during the 4th quarter. Global Retirement Partners LLC now owns 2,573 shares of the medical research company’s stock worth $620,000 after buying an additional 112 shares during the period. Finally, J.W. Cole Advisors Inc. acquired a new position in Amgen during the 4th quarter worth approximately $1,275,000. 76.41% of the stock is currently owned by institutional investors.
Amgen stock traded up $1.65 during trading on Friday, reaching $226.43. The company had a trading volume of 2,305,494 shares, compared to its average volume of 2,887,619. Amgen, Inc. has a 52 week low of $166.68 and a 52 week high of $244.99. The firm’s 50-day simple moving average is $228.36 and its 200 day simple moving average is $225.14. The firm has a market capitalization of $132.23 billion, a price-to-earnings ratio of 17.75, a price-to-earnings-growth ratio of 1.92 and a beta of 0.97. The company has a current ratio of 1.59, a quick ratio of 1.28 and a debt-to-equity ratio of 3.16.
The business also recently announced a quarterly dividend, which will be paid on Monday, June 8th. Investors of record on Monday, May 18th will be issued a $1.60 dividend. The ex-dividend date is Friday, May 15th. This represents a $6.40 dividend on an annualized basis and a yield of 2.83%. Amgen’s dividend payout ratio is currently 43.18%.
In related news, Director Ronald D. Sugar sold 1,000 shares of the stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $229.27, for a total value of $229,270.00. Following the completion of the transaction, the director now owns 16,482 shares of the company’s stock, valued at approximately $3,778,828.14. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director R Sanders Williams sold 425 shares of the stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $237.31, for a total transaction of $100,856.75. Following the completion of the transaction, the director now directly owns 5,834 shares of the company’s stock, valued at approximately $1,384,466.54. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 2,425 shares of company stock worth $563,477. 0.25% of the stock is owned by insiders.
A number of research analysts recently weighed in on the company. Raymond James raised Amgen from a “market perform” rating to an “outperform” rating and set a $255.00 price target on the stock in a research note on Sunday, March 29th. JPMorgan Chase & Co. reaffirmed a “hold” rating on shares of Amgen in a research note on Sunday, February 2nd. BidaskClub raised Amgen from a “sell” rating to a “hold” rating in a research note on Saturday, March 14th. Barclays began coverage on Amgen in a report on Thursday, February 27th. They set an “equal weight” rating and a $235.00 price objective for the company. Finally, Robert W. Baird lowered Amgen from a “neutral” rating to an “underperform” rating and boosted their price objective for the stock from $173.00 to $185.00 in a report on Friday, January 31st. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and seventeen have assigned a buy rating to the company’s stock. Amgen presently has a consensus rating of “Buy” and an average price target of $244.65.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Featured Story: What is the FTSE 100 index?
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.